The first recorded use in a pituitary tumor was in 2006, when an elderly male with recurrent prolactin-secreting pituitary carcinoma achieved stable prolactin levels and a significant reduction in the size of the primary tumor and metastases within 18 months of TMZ therapy [16]. Here, PRL is linked to pituitary adenocarcinoma.